NO20043919L - Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater - Google Patents
Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivaterInfo
- Publication number
- NO20043919L NO20043919L NO20043919A NO20043919A NO20043919L NO 20043919 L NO20043919 L NO 20043919L NO 20043919 A NO20043919 A NO 20043919A NO 20043919 A NO20043919 A NO 20043919A NO 20043919 L NO20043919 L NO 20043919L
- Authority
- NO
- Norway
- Prior art keywords
- hmg
- preparation
- acid derivatives
- coa reductase
- mevalonic acid
- Prior art date
Links
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical class OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 title 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 title 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/535—Organo-phosphoranes
- C07F9/5352—Phosphoranes containing the structure P=C-
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
- C07F15/004—Iridium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0073—Rhodium compounds
- C07F15/008—Rhodium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/04—Nickel compounds
- C07F15/045—Nickel compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/06—Cobalt compounds
- C07F15/065—Cobalt compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Quinoline Compounds (AREA)
- Indole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0204129.1A GB0204129D0 (en) | 2002-02-21 | 2002-02-21 | Process for the manufacture of organic compounds |
| PCT/EP2003/001738 WO2003070717A1 (en) | 2002-02-21 | 2003-02-20 | Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043919L true NO20043919L (no) | 2004-09-20 |
Family
ID=9931523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043919A NO20043919L (no) | 2002-02-21 | 2004-09-20 | Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7208623B2 (pl) |
| EP (1) | EP1478640A1 (pl) |
| JP (1) | JP2005520818A (pl) |
| KR (1) | KR100978970B1 (pl) |
| CN (1) | CN1318412C (pl) |
| AU (1) | AU2003218994B2 (pl) |
| BR (1) | BR0307801A (pl) |
| CA (1) | CA2473075A1 (pl) |
| EC (1) | ECSP045234A (pl) |
| GB (1) | GB0204129D0 (pl) |
| IL (1) | IL163279A (pl) |
| MX (1) | MXPA04008110A (pl) |
| NO (1) | NO20043919L (pl) |
| NZ (1) | NZ534394A (pl) |
| PL (1) | PL370596A1 (pl) |
| RU (1) | RU2335500C2 (pl) |
| WO (1) | WO2003070717A1 (pl) |
| ZA (1) | ZA200405436B (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0204129D0 (en) | 2002-02-21 | 2002-04-10 | Novartis Ag | Process for the manufacture of organic compounds |
| WO2004072040A1 (en) | 2003-02-12 | 2004-08-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of pitavastatin calcium |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| US20070179166A1 (en) * | 2003-12-24 | 2007-08-02 | Valerie Niddam-Hildesheim | Process for preparation of statins with high syn to anti ratio |
| US7851624B2 (en) * | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
| EP1634870A1 (en) * | 2004-08-27 | 2006-03-15 | Zhejiang Hisun Pharmaceutical Co. Ltd. | Process and intermediates for the selective synthesis of Fluvastatin |
| EP1817027A2 (en) * | 2004-09-27 | 2007-08-15 | Ranbaxy Laboratories Limited | Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof |
| WO2007017117A1 (en) * | 2005-07-28 | 2007-02-15 | Lek Pharmaceuticals D.D. | Process for the synthesis of rosuvastatin calcium |
| SI2024341T1 (sl) | 2006-05-03 | 2016-04-29 | Msn Laboratories Private Limited | Novi postopek za statine in njihove farmacevtsko sprejemljive soli |
| US8404841B2 (en) | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
| EP2079712A2 (en) * | 2006-10-31 | 2009-07-22 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin calcium |
| US8212035B2 (en) * | 2007-02-08 | 2012-07-03 | Aurobindo Pharma Ltd. | Process for preparation of rosuvastatin calcium field of the invention |
| KR20090018964A (ko) * | 2007-04-18 | 2009-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | Ｈｍｇ-ｃｏａ 환원 효소 억제제의 중간체의 제조 방법 |
| JP2010501643A (ja) * | 2007-07-12 | 2010-01-21 | テバ ファーマシューティカル インダストリーズ リミティド | 薄膜蒸発及び化学的手法によるロスバスタチン中間体の精製 |
| KR101063146B1 (ko) * | 2008-11-10 | 2011-09-07 | 미래파인켐 주식회사 | 피타바스타틴 중간체의 제조방법 및 이를 이용한 피타바스타틴 헤미 칼슘염의 제조방법 |
| US8487105B2 (en) | 2009-01-19 | 2013-07-16 | Msn Laboratories Limited | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof |
| EP2526099B1 (en) | 2010-01-18 | 2016-03-30 | MSN Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
| WO2012063254A1 (en) * | 2010-11-12 | 2012-05-18 | Hetero Research Foundation | Novel polymorphs of pitavastatin calcium |
| FR2970178B1 (fr) * | 2011-01-07 | 2014-06-20 | Liliane Therese Jacquot | Promedicaments pour une delivrance specifique au niveau du foie et une meilleure tolerance |
| CN103058925B (zh) * | 2011-11-02 | 2015-09-02 | 石药集团中奇制药技术（石家庄）有限公司 | 一种匹伐他汀钙的制备方法 |
| TWI516520B (zh) | 2014-10-31 | 2016-01-11 | 財團法人工業技術研究院 | 波長轉換聚合物、其製法及包含其之波長轉換裝置 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851427A (en) | 1985-10-25 | 1989-07-25 | Sandoz Pharm. Corp. | Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use |
| CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| SG44830A1 (en) | 1992-07-02 | 1997-12-19 | Hoechst Ag | Process for preparing tert-butyl 93R,5S) -6 Hydroxy-3,5-O-Isopropylidene-3, 5-Dihydroxyhexanoate |
| DE69518497T2 (de) | 1994-12-07 | 2001-04-19 | Japan Science And Technology Corp., Kawaguchi | Verfahren zur Herstellung eines Alkohols |
| US6184381B1 (en) | 1995-12-06 | 2001-02-06 | Japan Science & Technology Corp. | Process for preparing optically active compounds |
| JP3159661B2 (ja) * | 1997-02-21 | 2001-04-23 | 科学技術振興事業団 | 光学活性アルコール類の製造方法 |
| US6187961B1 (en) * | 1997-11-06 | 2001-02-13 | Roche Vitamins Inc. | Process for the preparation of trans-(R,R)-actinol |
| JPH11322649A (ja) * | 1998-03-16 | 1999-11-24 | Mitsubishi Chemical Corp | 光学活性アルコールの製造方法 |
| JPH11335385A (ja) * | 1998-05-20 | 1999-12-07 | Takasago Internatl Corp | 遷移金属錯体および該錯体を用いた光学活性アルコールの製造方法 |
| JP2000212110A (ja) * | 1999-01-27 | 2000-08-02 | Mitsubishi Chemicals Corp | 光学活性α―アルキルベンジルアルコ―ル類の製造方法 |
| JP3630002B2 (ja) * | 1999-03-03 | 2005-03-16 | 三菱化学株式会社 | 光学活性１，２−ジオール類の製造方法 |
| JP2000327659A (ja) * | 1999-03-15 | 2000-11-28 | Mitsubishi Chemicals Corp | 光学活性ピリジルアルコール類の製造方法 |
| US6211412B1 (en) * | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
| US6603015B2 (en) * | 1999-03-29 | 2003-08-05 | University Of Kansas | Synthesis of epothilones |
| JP2001104795A (ja) * | 1999-10-13 | 2001-04-17 | Mitsubishi Chemicals Corp | ルテニウム触媒組成物 |
| JP3720235B2 (ja) * | 2000-03-14 | 2005-11-24 | 高砂香料工業株式会社 | 光学活性ルテニウムホスフィン錯体の製造方法及び該錯体を用いた光学活性アルコールの製造方法 |
| ES2225330T3 (es) * | 2000-03-22 | 2005-03-16 | Hoffmann La Roche | Compuesto de piperidina y piperacina para empleo en el tratamiento de alzheimer. |
| CN1217930C (zh) | 2000-05-26 | 2005-09-07 | 西巴特殊化学品控股有限公司 | 吲哚衍生物的制备方法和该方法的中间体 |
| EP1305278B1 (en) | 2000-07-24 | 2004-11-03 | Chirotech Technology Limited | Ruthenium complexes and their use in asymmetric hydrogenation |
| GB0204129D0 (en) | 2002-02-21 | 2002-04-10 | Novartis Ag | Process for the manufacture of organic compounds |
-
2002
- 2002-02-21 GB GBGB0204129.1A patent/GB0204129D0/en not_active Ceased
-
2003
- 2003-02-20 PL PL03370596A patent/PL370596A1/pl not_active Application Discontinuation
- 2003-02-20 WO PCT/EP2003/001738 patent/WO2003070717A1/en not_active Ceased
- 2003-02-20 NZ NZ534394A patent/NZ534394A/en not_active IP Right Cessation
- 2003-02-20 RU RU2004128256/04A patent/RU2335500C2/ru not_active IP Right Cessation
- 2003-02-20 KR KR1020047013033A patent/KR100978970B1/ko not_active Expired - Fee Related
- 2003-02-20 AU AU2003218994A patent/AU2003218994B2/en not_active Ceased
- 2003-02-20 JP JP2003569624A patent/JP2005520818A/ja active Pending
- 2003-02-20 EP EP03714750A patent/EP1478640A1/en not_active Withdrawn
- 2003-02-20 BR BR0307801-9A patent/BR0307801A/pt not_active IP Right Cessation
- 2003-02-20 CA CA002473075A patent/CA2473075A1/en not_active Abandoned
- 2003-02-20 CN CNB038042886A patent/CN1318412C/zh not_active Expired - Fee Related
- 2003-02-20 US US10/504,655 patent/US7208623B2/en not_active Expired - Fee Related
- 2003-02-20 MX MXPA04008110A patent/MXPA04008110A/es active IP Right Grant
-
2004
- 2004-07-08 ZA ZA200405436A patent/ZA200405436B/en unknown
- 2004-07-29 IL IL163279A patent/IL163279A/en not_active IP Right Cessation
- 2004-08-16 EC EC2004005234A patent/ECSP045234A/es unknown
- 2004-09-20 NO NO20043919A patent/NO20043919L/no not_active Application Discontinuation
-
2007
- 2007-03-09 US US11/684,134 patent/US20070155970A1/en not_active Abandoned
-
2008
- 2008-07-23 US US12/220,259 patent/US20080312462A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ534394A (en) | 2006-10-27 |
| MXPA04008110A (es) | 2004-11-26 |
| KR100978970B1 (ko) | 2010-08-30 |
| BR0307801A (pt) | 2004-12-21 |
| PL370596A1 (pl) | 2005-05-30 |
| US20080312462A1 (en) | 2008-12-18 |
| RU2335500C2 (ru) | 2008-10-10 |
| RU2004128256A (ru) | 2005-06-27 |
| US20050159480A1 (en) | 2005-07-21 |
| IL163279A (en) | 2010-06-30 |
| CN1636004A (zh) | 2005-07-06 |
| WO2003070717A1 (en) | 2003-08-28 |
| US7208623B2 (en) | 2007-04-24 |
| AU2003218994A1 (en) | 2003-09-09 |
| GB0204129D0 (en) | 2002-04-10 |
| ECSP045234A (es) | 2004-09-28 |
| ZA200405436B (en) | 2005-06-17 |
| EP1478640A1 (en) | 2004-11-24 |
| CN1318412C (zh) | 2007-05-30 |
| KR20040111360A (ko) | 2004-12-31 |
| JP2005520818A (ja) | 2005-07-14 |
| CA2473075A1 (en) | 2003-08-23 |
| US20070155970A1 (en) | 2007-07-05 |
| AU2003218994B2 (en) | 2007-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL163279A (en) | Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives | |
| IL269976B (en) | Intermediate compounds for the preparation of quinazolinones as inhibitors of human phophatidylinositol 3-kinase delta | |
| NO20070753L (no) | Fremgangsmåte for fremstilling av dihydropteridinoner | |
| NO20050136D0 (no) | Fremgangsmate for fremstilling av mikropartikler | |
| NO20043158L (no) | Substituerte kinazolinderivater som inhibitorer av aurorakinaser | |
| NO20054143D0 (no) | Pyrimidinderivater for forhindringen av HIV-infeksjon | |
| NO20054880D0 (no) | Azaspiroalkanderivater som inhibitorer av metallproeaser | |
| EP1951686A4 (en) | CHINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PRODUCTION THEREOF | |
| HUP0303624A3 (en) | N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad and process for preparation of the compounds | |
| AU3368400A (en) | Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammationassociated with pulmonary disease | |
| NO20033408D0 (no) | Fremgangsmåte for fremstilling av krystallinske nanopartikler | |
| NO20044814L (no) | Fremgangsmate for fremstilling av combretastaniner | |
| AU2002303145A1 (en) | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases | |
| IL172629A0 (en) | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | |
| WO2008010087A3 (en) | Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof | |
| IL172018A0 (en) | Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases | |
| SI2341054T1 (sl) | Postopek za pripravo zaviralcev HMG-CoA reduktaz | |
| NO20044332L (no) | Forbedret fremgangsmate for fremstilling av nevirapine | |
| AU2002359034A1 (en) | Process for the preparation of simvastatin | |
| AU2002337601A1 (en) | Process for the preparation of simvastatin | |
| NO20043455L (no) | Fremgangsmate for fremstilling av 7alfa-metylsteroider | |
| HK1072421A (en) | Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives | |
| NO20044629L (no) | Fremgangsmate til fremstilling av sure salter av gemifloksasin. | |
| PL367885A1 (pl) | Analogi metylowe symwastatyny jako nowe inhibitory reduktazy HMG-CoA | |
| NO20052396D0 (no) | Fremgangsmate for fremstilling av spirolactonforbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |